APA (7th ed.) Citation

Q, C., Y, Z., H, Z., X, Y., X, L., X, W., . . . T, Y. (2023). Corrigendum to "Bone marrow mesenchymal stem cells alleviate the daunorubicin-induced subacute myocardial injury in rats through inhibiting infiltration of T lymphocytes and antigen-presenting cells" [Biomed. Pharmacother. 121 (2020) 109157]. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 164, 114940. https://doi.org/10.1016/j.biopha.2023.114940

Chicago Style (17th ed.) Citation

Q, Chen, et al. "Corrigendum to "Bone Marrow Mesenchymal Stem Cells Alleviate the Daunorubicin-induced Subacute Myocardial Injury in Rats Through Inhibiting Infiltration of T Lymphocytes and Antigen-presenting Cells" [Biomed. Pharmacother. 121 (2020) 109157]." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 164 (2023): 114940. https://doi.org/10.1016/j.biopha.2023.114940.

MLA (9th ed.) Citation

Q, Chen, et al. "Corrigendum to "Bone Marrow Mesenchymal Stem Cells Alleviate the Daunorubicin-induced Subacute Myocardial Injury in Rats Through Inhibiting Infiltration of T Lymphocytes and Antigen-presenting Cells" [Biomed. Pharmacother. 121 (2020) 109157]." Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 164, 2023, p. 114940, https://doi.org/10.1016/j.biopha.2023.114940.